Revenue $71.67B, up 6.7% on a year earlier. Fees and Other Revenues $4.37B, up 5.5%. Pharmacy Revenues $57.17B, up 6.6%. Diluted EPS $6.29 against $5.71.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $71.67B | $68.49B | $67.18B | +6.7% |
| Operating income | $2.68B | $2.36B | $2.31B | +16.0% |
| Net income | $1.66B | $1.65B | $1.53B | +8.4% |
| Diluted EPS | $6.29 | $6.26 | $5.71 | |
| Operating cash flow | -$421.00M | $1.13B | -$1.89B | |
| Capital expenditures | -$297.00M | -$267.00M | -$285.00M | |
| Free cash flow | -$718.00M | $864.00M | -$2.17B | |
| Dividend per share | $1.56 | $1.56 | $1.51 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Fees and Other Revenues | $4.37B | $4.14B | +5.5% |
| Pharmacy Revenues | $57.17B | $53.65B | +6.6% |
| Evernorth Adjusted Revenues | $61.47B | $57.83B | +6.3% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Cigna Group (CI) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/CI/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
